Last reviewed · How we verify
Period 1 - Treatment Sequence AC
At a glance
| Generic name | Period 1 - Treatment Sequence AC |
|---|---|
| Sponsor | Theriva Biologics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants (PHASE1)
- Study About Whether Atirmociclib/PF-07220060 Proportionally Increases Exposure as Dose Increases in Healthy Participants (PHASE1)
- A Drug-Drug Interaction Study of CTL0901 and CTL0902 Compared to Coadministration in Healthy Adult Volunteers (PHASE1)
- A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants (PHASE1)
- Pharmacokinetics (PK) Drug Interaction Study of Milademetan and Itraconazole or Posaconazole in Healthy Participants (EARLY_PHASE1)
- A Study to Evaluate the Effect of SYN-004 on the PK of IV Ceftriaxone in Adults With a Functioning Ileostomy (PHASE1, PHASE2)
- A Relative Bioavailability Study of 20 mg Famotidine Tablets Under Fasting Condition (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Period 1 - Treatment Sequence AC CI brief — competitive landscape report
- Period 1 - Treatment Sequence AC updates RSS · CI watch RSS
- Theriva Biologics, Inc. portfolio CI